Schedule 13D ownership disclosure
AUTOLUS THERAPEUTICS LTD
American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share · CUSIP: 05280R100
Event date: 2026-11-06
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BXLS V - Autobahn L.P.
Shares: 20,485,611 · Class: 7.6%
- Blackstone Life Sciences Associates V (CYM) L.L.C.
Shares: 20,485,611 · Class: 7.6%
- BXLS V L.L.C.
Shares: 20,485,611 · Class: 7.6%
- Blackstone Holdings II L.P.
Shares: 20,485,611 · Class: 7.6%
- Blackstone Holdings I/II GP L.L.C.
Shares: 20,485,611 · Class: 7.6%
- Blackstone Inc.Reported CIK 0001393818
Shares: 20,485,611 · Class: 7.6%
- Blackstone Group Management L.L.C.
Shares: 20,485,611 · Class: 7.6%
- Stephen A. Schwarzman
Shares: 20,485,611 · Class: 7.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-455574
- Form type
- SCHEDULE 13D/A
- Filer
- Autolus Therapeutics plc
- CIK
- CIK 1730463
- Filed
- Nov 10, 2026
- Reporting period
- Nov 06, 2026
- Description
- Schedule 13D beneficial ownership